SI2970398T1 - Prefuzijski proteini RSV in njihova uporaba - Google Patents

Prefuzijski proteini RSV in njihova uporaba

Info

Publication number
SI2970398T1
SI2970398T1 SI201432090T SI201432090T SI2970398T1 SI 2970398 T1 SI2970398 T1 SI 2970398T1 SI 201432090 T SI201432090 T SI 201432090T SI 201432090 T SI201432090 T SI 201432090T SI 2970398 T1 SI2970398 T1 SI 2970398T1
Authority
SI
Slovenia
Prior art keywords
proteins
prefusion rsv
prefusion
rsv
Prior art date
Application number
SI201432090T
Other languages
English (en)
Slovenian (sl)
Inventor
Jeffrey Boyington
Ivelin Stefanov Georgiev
Marie Pancera
Cinque Soto
Sanjay Srivatsan
Guillaume Stewart-Jones
Peter D. Kwong
Barney S. Graham
Jason S. Mclellan
Michael Gordon Joyce
Masaru Kanekiyo
Baoshan Zhang
Lei Chen
Man Chen
Gwo-Yu Chuang
Jason Gorman
Yongping Yang
Tongqing Zhou
Mallika Sastry
Gilad Ofek
Original Assignee
The United States of America, as represented by the Secretary, Deparment of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States of America, as represented by the Secretary, Deparment of Health and Human Services filed Critical The United States of America, as represented by the Secretary, Deparment of Health and Human Services
Publication of SI2970398T1 publication Critical patent/SI2970398T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18523—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
SI201432090T 2013-03-13 2014-03-13 Prefuzijski proteini RSV in njihova uporaba SI2970398T1 (sl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361780910P 2013-03-13 2013-03-13
US201361798389P 2013-03-15 2013-03-15
US201361857613P 2013-07-23 2013-07-23
US201361863909P 2013-08-09 2013-08-09
PCT/US2014/026714 WO2014160463A1 (en) 2013-03-13 2014-03-13 Prefusion rsv f proteins and their use
EP14775224.0A EP2970398B1 (en) 2013-03-13 2014-03-13 Prefusion rsv f proteins and their use

Publications (1)

Publication Number Publication Date
SI2970398T1 true SI2970398T1 (sl) 2024-09-30

Family

ID=51625430

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201432090T SI2970398T1 (sl) 2013-03-13 2014-03-13 Prefuzijski proteini RSV in njihova uporaba

Country Status (21)

Country Link
US (5) US10017543B2 (enExample)
EP (2) EP4421177A3 (enExample)
JP (4) JP6703475B2 (enExample)
KR (3) KR20250023601A (enExample)
CN (2) CN112851766A (enExample)
AU (5) AU2014243756B2 (enExample)
CA (1) CA2902877A1 (enExample)
DK (1) DK2970398T3 (enExample)
ES (1) ES2981623T3 (enExample)
FI (1) FI2970398T3 (enExample)
HR (1) HRP20240996T1 (enExample)
HU (1) HUE067333T2 (enExample)
LT (1) LT2970398T (enExample)
MX (2) MX385818B (enExample)
PL (1) PL2970398T3 (enExample)
PT (1) PT2970398T (enExample)
RS (1) RS65760B1 (enExample)
RU (1) RU2761631C2 (enExample)
SI (1) SI2970398T1 (enExample)
SM (1) SMT202400297T1 (enExample)
WO (1) WO2014160463A1 (enExample)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
EP2950886B1 (en) 2013-02-01 2019-12-18 Medlmmune, LLC Respiratory syncytial virus f protein epitopes
US10017543B2 (en) 2013-03-13 2018-07-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
US9738689B2 (en) * 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
EP3798310A1 (en) 2013-03-14 2021-03-31 Emory University Recombinant rsv with silent mutations, vaccines, and methods related thereto
JP6671276B2 (ja) 2013-03-27 2020-03-25 セダーズ−シナイ メディカル センター Ｔｌ１ａ機能および関連するシグナル経路の抑制による線維症および炎症の緩和および回復
EA035522B1 (ru) 2013-04-25 2020-06-29 Янссен Вэксинс Энд Превеншн Б.В. Стабильные растворимые f-полипептиды rsv в конформации "до слияния"
JP6679475B2 (ja) * 2013-06-17 2020-04-15 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
JP6685903B2 (ja) 2013-07-25 2020-04-22 アバター・メディカル・エルエルシー 立体構造的に安定化されたｒｓｖ融合前ｆタンパク質
CN105473158B (zh) 2013-08-21 2021-04-13 库瑞瓦格股份公司 呼吸道合胞病毒(rsv)疫苗
EP3049107A1 (en) * 2013-09-24 2016-08-03 Massachusetts Institute of Technology Self-assembled nanoparticle vaccines
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
CA2974359A1 (en) * 2015-01-20 2016-07-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant parainfluenza virus expressing a chimeric f protein and uses thereof
SG11201706118XA (en) * 2015-01-29 2017-08-30 Agency Science Tech & Res Nanocapsules carrying chikungunya-associated peptides
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US10456462B2 (en) * 2015-07-07 2019-10-29 Janssen Vaccines & Preventions B.V. Vaccine against RSV
JP6840718B2 (ja) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
FR3041962B1 (fr) * 2015-10-01 2018-01-05 Lab Francais Du Fractionnement Procede d'enrichissement d'une preparation d'immunoglobulines en immunoglobulines anti-rsv et preparation ainsi enrichie
ES2922760T3 (es) 2015-10-22 2022-09-20 Modernatx Inc Vacunas de virus respiratorios
SG10201914006UA (en) * 2015-10-22 2020-03-30 Modernatx Inc Respiratory syncytial virus vaccine
CA3003726A1 (en) * 2015-10-29 2017-05-04 Emory University Chimeric rsv, immunogenic compositions, and methods of use
CN108738312A (zh) 2015-12-23 2018-11-02 辉瑞公司 Rsv f蛋白突变体
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2
WO2017172890A1 (en) * 2016-03-29 2017-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion rsv f proteins and their use
AU2017248021B2 (en) 2016-04-05 2021-08-12 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F proteins
US10729757B2 (en) 2016-04-05 2020-08-04 Janssen Vaccines & Prevention B.V. Vaccine against RSV
IL245059A0 (en) 2016-04-12 2016-06-30 Technion Res & Dev Foundation Electrospun scaffolds from extracellular matrix
DK3464331T3 (da) 2016-05-30 2021-01-18 Janssen Vaccines & Prevention Bv Stabiliserede præfusions-rsv f-proteiner
EP3474893A1 (en) 2016-06-27 2019-05-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
CN106119287B (zh) * 2016-08-29 2019-10-11 广东华南疫苗股份有限公司 一种表达呼吸道合胞病毒f蛋白的重组载体及方法
EP3518967A4 (en) 2016-10-03 2020-04-29 University of Massachusetts Methods for immunizing pre-immune subjects against respiratory syncytial virus (rsv)
WO2018081289A2 (en) 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion piv f immunogens and their use
KR20190082815A (ko) * 2016-10-26 2019-07-10 세다르스-신나이 메디칼 센터 중화 항-tl1a 단일 클론 항체
TWI683826B (zh) * 2016-11-22 2020-02-01 國立臺灣大學 重組ｒｓｖ抗原
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018107088A2 (en) 2016-12-08 2018-06-14 Modernatx, Inc. Respiratory virus nucleic acid vaccines
CA3043790A1 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
CN108265079A (zh) * 2017-01-02 2018-07-10 刘昕 一种新型呼吸道合胞体病毒pre-F融合蛋白载体的制备方法
US11464848B2 (en) 2017-03-15 2022-10-11 Modernatx, Inc. Respiratory syncytial virus vaccine
WO2018175518A1 (en) * 2017-03-22 2018-09-27 The Scripps Research Institute Mini-protein immunogens displayng neutralization epitopes for respiratory syncytial virus (rsv)
SG11201908999QA (en) 2017-04-04 2019-10-30 Univ Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
EP3624844A1 (en) 2017-05-17 2020-03-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
IE87439B1 (en) 2017-05-30 2023-10-11 Glaxosmithkline Biologicals Sa Novel methods for manufacturing an adjuvant
KR20200018483A (ko) 2017-06-14 2020-02-19 비로메틱스 아게 호흡기 합포체 바이러스에 대한 방어를 위한 고리형 펩티드
WO2019032480A1 (en) * 2017-08-07 2019-02-14 Avatar Medical, Llc PROTEINS F PRE-FUSION OF RSV STABILIZED IN TERMS OF CONFORMATION
CN111163800A (zh) 2017-09-15 2020-05-15 扬森疫苗与预防公司 用于安全诱导针对rsv的免疫的方法
JP2019092481A (ja) * 2017-11-27 2019-06-20 国立大学法人東京工業大学 ヘテロタンパク質ケージ
CN111670044A (zh) 2017-12-01 2020-09-15 葛兰素史密丝克莱恩生物有限公司 皂苷纯化
MA54676A (fr) 2018-01-29 2021-11-17 Modernatx Inc Vaccins à base d'arn contre le vrs
WO2019147749A2 (en) 2018-01-29 2019-08-01 Merck Sharp & Dohme Corp. Stabilized rsv f proteins and uses thereof
AU2019228551B2 (en) 2018-02-28 2025-07-24 University Of Washington Self-assembling nanostructure vaccines
WO2019178521A1 (en) * 2018-03-16 2019-09-19 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for vaccination against respiratory syncitial virus infection
AU2019247034B2 (en) * 2018-04-03 2025-12-11 Sanofi Antigenic respiratory syncytial virus polypeptides
WO2019195316A1 (en) * 2018-04-03 2019-10-10 Sanofi Ferritin proteins
CN112512565A (zh) * 2018-04-03 2021-03-16 赛诺菲 抗原性流感-铁蛋白多肽
JP7614842B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性エプスタインバーウイルスポリペプチド
US20210170017A1 (en) * 2018-04-17 2021-06-10 Curevac Ag Novel rsv rna molecules and compositions for vaccination
EP3784699A4 (en) 2018-04-25 2022-04-13 Prometheus Biosciences, Inc. OPTIMIZED ANTI-TL1A ANTIBODIES
WO2019211630A2 (en) 2018-05-04 2019-11-07 SpyBiotech Limited Vaccine composition
CN110684747B (zh) * 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
JP2021532764A (ja) 2018-07-31 2021-12-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 抗原精製方法
CN112930192A (zh) 2018-08-03 2021-06-08 美国政府(由卫生和人类服务部的部长所代表) 尼帕病毒免疫原及其用途
JP2021533162A (ja) 2018-08-07 2021-12-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロセス及びワクチン
KR20210091749A (ko) * 2018-11-13 2021-07-22 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합전 rsv f 단백질
WO2020102603A1 (en) * 2018-11-14 2020-05-22 Rubryc Therapeutics, Inc. Engineered cd25 polypeptides and uses thereof
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
EP3932424A4 (en) 2019-02-28 2022-10-12 KM Biologics Co., Ltd. Rsv f/g chimeric vaccine
CN114080393A (zh) 2019-06-05 2022-02-22 葛兰素史克生物有限公司 皂苷纯化
EP4025587A1 (en) 2019-09-04 2022-07-13 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
MX2022004942A (es) 2019-10-24 2022-07-27 Prometheus Biosciences Inc Anticuerpos humanizados contra el ligando 1a de tipo tnf (tl1a) y usos de los mismos.
BR112022011422A2 (pt) * 2019-12-11 2022-08-30 Us Health Imunógenos para vírus da caxumba e do sarampo e seus usos
AU2020411873B2 (en) * 2019-12-23 2024-07-25 Mitsubishi Tanabe Pharma Corporation Mutant RSV F protein and use thereof
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2021155243A1 (en) * 2020-01-30 2021-08-05 Modernatx, Inc. Respiratory virus immunizing compositions
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
CN116096407A (zh) * 2020-04-29 2023-05-09 美国政府(由卫生和人类服务部的部长所代表) 重组人偏肺病毒f蛋白及其用途
JP2023530229A (ja) 2020-05-29 2023-07-14 キュアバック エスイー 核酸ベースの混合ワクチン
IL298131A (en) * 2020-05-29 2023-01-01 Univ Texas Transgenic coronavirus spike protein(s) and methods of using it
WO2021249009A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Rsv vaccine compositions, methods, and uses thereof
JP2022023814A (ja) 2020-07-27 2022-02-08 ファイザー・インク 組換え生産された三量体型のｒｓｖタンパク質の精製方法
JP2022023813A (ja) 2020-07-27 2022-02-08 ファイザー・インク 組換え生産されたｒｓｖタンパク質の精製方法における陰イオン交換クロマトグラフィー用洗浄溶液の改良
CN112226444B (zh) * 2020-08-25 2022-11-04 北京交通大学 呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、重组腺病毒载体及其应用产品
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
IL301950B2 (en) 2020-10-09 2025-09-01 Univ Texas Pre-stabilized hmpv f proteins
JP2023547197A (ja) 2020-10-28 2023-11-09 サノフィ・パスツール Ｔｌｒ４アゴニストを含有するリポソーム、その製造および使用
CN112592928B (zh) * 2020-12-31 2021-08-31 北京鼎成肽源生物技术有限公司 冠状病毒的融合基因、融合蛋白、重组载体、通用型dc疫苗及其制备方法
MX2023009738A (es) * 2021-02-19 2023-08-30 Janssen Vaccines & Prevention Bv Antigenos de rsv fb prefusion estabilizados.
AU2022251938A1 (en) 2021-04-02 2023-11-16 Bureau D’Études Biologiques Scientifiques Et Médicales IMMUNOGENIC COMPOSITION CONTAINING AN ANTIGEN AND AN ADJUVANT COMPRISING AL-MOFs
US12304929B2 (en) * 2021-04-12 2025-05-20 Sk Bioscience Co., Ltd. Recombinant RSV live vaccine strain and the preparing method thereof
EP4323383A4 (en) * 2021-04-15 2025-08-13 Merck Sharp & Dohme Llc ROTAVIRUS VECTORS FOR HETEROLOGOUS GENE DELIVERY
MX2024001867A (es) * 2021-08-10 2024-03-04 Icosavax Inc Vacuna de particulas similares a virus para el virus respiratorio sincitial.
KR20230047033A (ko) * 2021-09-29 2023-04-06 에스케이바이오사이언스(주) 재조합된 약독화 rsv 생백신 및 이를 제조하는 방법
WO2023091766A2 (en) * 2021-11-19 2023-05-25 RNAimmune, Inc. Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines
KR102785012B1 (ko) * 2021-12-14 2025-03-20 경희대학교 산학협력단 Rsv 항원 단백질을 포함하는 바이러스 유사입자 및 이를 이용한 백신
WO2023208206A1 (zh) * 2022-04-29 2023-11-02 北京新合睿恩生物医疗科技有限公司 Rsv f蛋白突变体及其应用
EP4532725A1 (en) * 2022-05-31 2025-04-09 VLP Therapeutics Japan, Inc. Modified vaccine design developments
WO2023237649A1 (en) * 2022-06-10 2023-12-14 Glaxosmithkline Biologicals Sa Rsv vaccination with trimeric rsv f fusion protein
WO2024041773A1 (en) * 2022-08-22 2024-02-29 Glaxosmithkline Biologicals Sa Rsv-f proteins
WO2024069420A2 (en) 2022-09-29 2024-04-04 Pfizer Inc. Immunogenic compositions comprising an rsv f protein trimer
CN116478296B (zh) * 2022-10-17 2024-02-23 厦门大学 截短的呼吸道合胞病毒f蛋白及其用途
IL320459A (en) 2022-10-27 2025-06-01 Pfizer Rna molecules encoding rsv-f and vaccines containing them
EP4608441A1 (en) 2022-10-27 2025-09-03 Pfizer Inc. Immunogenic compositions against influenza and rsv
KR20250099727A (ko) * 2022-11-04 2025-07-02 사노피 파스퇴르 인크 호흡기 세포융합 바이러스 rna 백신접종
EP4615980A1 (en) * 2022-11-09 2025-09-17 Nykode Therapeutics ASA Co-expression of constructs and polypeptides
KR102531775B1 (ko) 2022-11-11 2023-05-15 대한민국 Rsv f 항체 또는 이의 항원 결합 단편
CN116284266B (zh) * 2022-11-21 2024-01-19 怡道生物科技(苏州)有限公司 突变型呼吸道合胞病毒融合前f蛋白及其应用
WO2024115561A1 (en) * 2022-12-01 2024-06-06 Glaxosmithkline Biologicals Sa Vaccination against rsv
US20240252612A1 (en) 2022-12-11 2024-08-01 Pfizer Inc. Immunogenic compositions and uses thereof
AU2024208950A1 (en) * 2023-01-17 2025-07-17 The Scripps Research Institute Engineered paramyxovirus soluble fusion (f) proteins and related vaccines
KR20250122511A (ko) 2023-01-18 2025-08-13 화이자 인코포레이티드 호흡기 질환에 대한 백신
AU2023427858A1 (en) * 2023-02-03 2025-05-15 Vernagen, LLC Respiratory syncytial virus mrna vaccine
WO2024164020A2 (en) * 2023-02-03 2024-08-08 The Trustees Of Columbia University In The City Of New York Methods of inhibiting paramyxoviridae fusion to a target cell
CR20250352A (es) * 2023-02-21 2025-10-07 Msd Int Business Gmbh Proteínas de fusión de rsv triméricas estabilizadas sin un dominio de trimerización heterólogo.
WO2024175040A1 (en) * 2023-02-22 2024-08-29 Everest Medicines (China) Co., Ltd. RSV mRNA VACCINES
WO2024193380A1 (zh) * 2023-03-17 2024-09-26 成都威斯克生物医药有限公司 抗呼吸道合胞病毒感染的疫苗
CN116536357A (zh) * 2023-04-17 2023-08-04 中国医学科学院输血研究所 构建CRISPR/Cas12a中sgRNA剪切活性筛选系统的方法
CN118108812B (zh) * 2023-05-04 2025-04-15 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
CN118994329A (zh) * 2023-05-18 2024-11-22 北京微星生物科技有限公司 融合前rsv f蛋白及其应用
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
CN117050149B (zh) * 2023-05-19 2025-12-12 珠海丽凡达生物技术有限公司 包含人呼吸道合胞病毒抗原的免疫组合物及其制备方法和应用
CN119019514A (zh) * 2023-05-25 2024-11-26 江苏瑞科生物技术股份有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
WO2024251281A1 (zh) * 2023-06-07 2024-12-12 四川三叶草生物制药有限公司 Rsv疫苗组合物、方法及其用途
AR132981A1 (es) * 2023-06-16 2025-08-13 Glaxosmithkline Biologicals Sa Proteínas rsv-f sustituidas con cisteína
TW202515531A (zh) 2023-07-07 2025-04-16 美商輝瑞股份有限公司 兩親性ｔｌｒ７／８佐劑及其用途
CN119431524A (zh) * 2023-08-07 2025-02-14 北京新合睿恩生物医疗科技有限公司 Rsv融合前构象f蛋白的突变体及其应用
WO2025092933A1 (zh) * 2023-10-31 2025-05-08 上海蓝鹊生物医药有限公司 一种rsv抗原、核酸、重组表达载体、药物组合物及其应用
CN120022355A (zh) * 2023-11-22 2025-05-23 长春百克生物科技股份公司 一种mRNA疫苗及其应用
CN117304278B (zh) * 2023-11-28 2024-04-16 江苏瑞科生物技术股份有限公司 一种重组rsv f蛋白及其应用
WO2025126071A1 (en) 2023-12-14 2025-06-19 Pfizer Inc. Rna molecules
WO2025127857A1 (ko) * 2023-12-15 2025-06-19 에스케이바이오사이언스(주) 변이 rsv 단백질
KR102816014B1 (ko) 2023-12-20 2025-06-02 에스케이바이오사이언스(주) Rsv 의 가용성 f 단백질을 생성하기 위한 재조합 전구체 폴리펩티드 및 이의 이용
CN117567652B (zh) * 2024-01-19 2024-05-14 北京安百胜生物科技有限公司 一种重组呼吸道合胞病毒颗粒抗原
CN117586425B (zh) * 2024-01-19 2024-06-14 北京安百胜生物科技有限公司 一种重组呼吸道合胞病毒颗粒抗原其制备方法和应用
CN117586359A (zh) * 2024-01-19 2024-02-23 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
CN117586357B (zh) * 2024-01-19 2024-07-09 北京安百胜生物科技有限公司 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽
CN117645655B (zh) * 2024-01-26 2024-05-24 普大生物科技(泰州)有限公司 一种肺炎球菌多糖-rsv重组蛋白结合疫苗及其制备方法
WO2025163460A2 (en) 2024-01-30 2025-08-07 Pfizer Inc. Vaccines against respiratory diseases
WO2025186719A1 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions and uses thereof
CN118440937B (zh) * 2024-04-09 2025-02-25 嘉译生物医药(杭州)有限公司 新型的人合胞病毒RSV B mRNA疫苗
CN118580323B (zh) * 2024-05-22 2025-06-17 苏州聚微生物科技有限公司 Rsv融合前f蛋白的突变体及其制备和应用
CN118406159B (zh) * 2024-05-22 2025-07-08 苏州聚微生物科技有限公司 RSV pre-F截短体及其生产方法和应用
CN118496324B (zh) * 2024-05-22 2025-10-21 苏州聚微生物科技有限公司 RSV pre-F突变体及其生产方法和用途
CN118480560B (zh) * 2024-07-09 2024-11-26 北京悦康科创医药科技股份有限公司 呼吸道合胞病毒mRNA疫苗及其制备方法和应用
CN119074910A (zh) * 2024-08-30 2024-12-06 中国医学科学院病原生物学研究所 以麻疹减毒活疫苗为载体的重组呼吸道合胞病毒疫苗及其制备方法
CN119176859B (zh) * 2024-11-26 2025-03-14 北京成大天和生物科技有限公司 呼吸道合胞病毒f蛋白突变体及其应用
CN119371496B (zh) * 2024-12-26 2025-03-25 北京华诺泰生物医药科技有限公司 一种呼吸道合胞病毒f蛋白突变体及其应用

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US472209A (en) 1892-04-05 Vacuum-pan
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
CA1236641A (en) 1984-07-06 1988-05-10 Motoaki Tanaka Copolymer of lactic acid and glycolic acid and method for producing same
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JP2551756B2 (ja) 1985-05-07 1996-11-06 武田薬品工業株式会社 ポリオキシカルボン酸エステルおよびその製造法
US4707543A (en) 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5726292A (en) 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
CA1336955C (en) * 1988-09-20 1995-09-12 Peter R. Paradiso Respiratory syncytial virus: vaccines and diagnostic assays
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
CA2129514A1 (en) 1992-03-12 1993-09-16 M. Amin Khan Controlled released acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
CA2142007C (en) 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
SK282843B6 (sk) 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
PL181241B1 (pl) 1993-11-17 2001-06-29 Deutsche Om Arzneimittel Gmbh Disacharydy beta(1 6)glukozoaminowe, sposób wytwarzania disacharydu beta(1 6) glukozoaminowego, zawierająca je kompozycja farmaceutyczna i środek immunomodulujący i/lub przeciwnowotworowy oraz szczepionka
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
DE69535178T2 (de) 1994-06-10 2006-12-14 Genvec, Inc. Adenoviren-vektor systeme und zelllinien
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
DE69535036T3 (de) 1994-07-15 2011-07-07 The University of Iowa Research Foundation, IA Immunomodulatorische oligonukleotide
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
US5856462A (en) 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
JP2002511771A (ja) * 1998-06-10 2002-04-16 インサイト・ファーマスーティカルズ・インコーポレイテッド 新規なカルボキシペプチダーゼインヒビター
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
KR100787073B1 (ko) 2000-06-28 2007-12-21 글리코파이, 인크. 변형된 당단백질의 제조방법
US20030232061A1 (en) 2001-10-18 2003-12-18 Fouchier Ronaldus Adrianus Maria Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
WO2002072012A2 (en) 2001-03-09 2002-09-19 Id Biomedical Corporation Of Quebec A novel proteosome-liposaccharide vaccine adjuvant
ATE404561T1 (de) 2001-04-17 2008-08-15 Dainippon Sumitomo Pharma Co Neue adeninderivate
JP2005503797A (ja) 2001-09-13 2005-02-10 ジェンベク、インコーポレイティッド アデノウイルスベクター及び関連する系、並びに製造及び使用の方法
WO2003029416A2 (en) 2001-10-01 2003-04-10 Uab Research Foundation Recombinant respiratory syncytial viruses with deleted surface glycoprotein genes and uses thereof
US20040014779A1 (en) 2001-11-16 2004-01-22 3M Innovative Properties Company Methods and compositions related to IRM compounds and toll-like recptor pathways
TWI405851B (zh) 2002-02-21 2013-08-21 麥迪紐有限責任公司 間質肺病毒株及其作為疫苗調配物及作為表現抗原性序列之載體之應用
WO2004010935A2 (en) 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
JP4752001B2 (ja) 2002-10-16 2011-08-17 ザ スクリプス リサーチ インスティチュート 糖蛋白質合成
WO2004071459A2 (en) 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
AU2004273776B2 (en) 2003-04-25 2010-07-08 Medimmune, Llc Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
EP2494987A1 (en) 2003-04-25 2012-09-05 MedImmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
US8637234B2 (en) 2004-04-16 2014-01-28 Uab Research Foundation Molecular scaffolds for HIV-1 epitopes
US8647818B2 (en) 2005-02-18 2014-02-11 UAB Research Foundation, University of Alabama—Birmingham Molecular scaffolds for HIV-1 immunogens
AU2006223138B2 (en) 2005-03-10 2012-04-05 Medimmune, Llc Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
US7728106B2 (en) 2005-07-01 2010-06-01 University Of Maryland Biotechnology Institute HIV-1 glycopeptides and derivatives; preparation and applications thereof
WO2007133855A2 (en) 2006-03-27 2007-11-22 University Of Maryland Biotechnology Institute Glycoprotein synthesis and remodeling by enzymatic transglycosylation
WO2008025015A2 (en) 2006-08-25 2008-02-28 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Epitope-protein scaffolds and their use
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
WO2009012155A2 (en) 2007-07-13 2009-01-22 Medimmune, Llc Preparation of negative-stranded rna viruses by electroporation
EP2222710B8 (en) * 2007-12-24 2016-10-12 ID Biomedical Corporation of Quebec Recombinant rsv antigens
ES2937147T3 (es) 2007-12-27 2023-03-24 Univ Zuerich Vectores arenavíricos defectuosos en la replicación
WO2010075491A2 (en) * 2008-12-24 2010-07-01 University Of Rochester Recombinant expression of self-folding neutralizing epitope-bearing subdomains of the respiratory syncytial virus attachment and fusion proteins
KR20120026526A (ko) 2009-05-12 2012-03-19 트랜스진 에스.에이. 불멸화 조류 세포주 및 그의 용도
CA2766205A1 (en) * 2009-06-24 2010-12-29 Id Biomedical Corporation Of Quebec Vaccine comprising at least two paramyxovirus f protein antigens
HUE028085T2 (en) 2009-06-24 2016-11-28 Glaxosmithkline Biologicals Sa Recombinant RSV antigens
CN102639147B (zh) 2009-07-15 2015-11-25 诺华股份有限公司 Rsv f 蛋白组合物和其制作方法
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CA2776249C (en) 2009-10-06 2021-01-19 Medimmune Ltd Rsv-specific binding molecule
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
NO2707385T3 (enExample) * 2011-05-13 2018-02-17
CN102210860B (zh) 2011-05-31 2012-11-21 昆明理工大学 一种结核分枝杆菌tb10．4-f1融合蛋白疫苗及制备方法
ES2395677B1 (es) * 2011-07-29 2013-12-26 Instituto De Salud Carlos Iii Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma.
SG11201500573RA (en) * 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
CN104853769A (zh) * 2012-11-20 2015-08-19 葛兰素史密丝克莱恩生物有限公司 Rsv f融合前三聚体
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
US10017543B2 (en) * 2013-03-13 2018-07-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
CN105722856B (zh) 2013-03-15 2019-04-16 厦门大学 Rsv融合蛋白的表位以及识别其的抗体
EA035522B1 (ru) 2013-04-25 2020-06-29 Янссен Вэксинс Энд Превеншн Б.В. Стабильные растворимые f-полипептиды rsv в конформации "до слияния"

Also Published As

Publication number Publication date
JP2020089384A (ja) 2020-06-11
MX2021010519A (es) 2021-10-01
CA2902877A1 (en) 2014-10-02
US11130785B2 (en) 2021-09-28
ES2981623T3 (es) 2024-10-10
AU2014243756B2 (en) 2018-09-27
KR102450375B1 (ko) 2022-10-04
US20240018193A1 (en) 2024-01-18
AU2018282476B2 (en) 2020-12-10
FI2970398T3 (fi) 2024-08-06
EP2970398B1 (en) 2024-05-08
AU2014243756A1 (en) 2015-09-17
AU2021201468B2 (en) 2022-11-24
PT2970398T (pt) 2024-06-07
DK2970398T3 (da) 2024-08-05
JP2022089818A (ja) 2022-06-16
KR102766946B1 (ko) 2025-02-12
AU2025203614A1 (en) 2025-06-12
SMT202400297T1 (it) 2024-09-16
EP2970398A4 (en) 2016-08-24
MX385818B (es) 2025-03-18
CN105473604A (zh) 2016-04-06
JP2016519658A (ja) 2016-07-07
HRP20240996T1 (hr) 2024-10-25
MX2015013065A (es) 2016-06-06
RU2021132097A (ru) 2022-03-03
EP4421177A3 (en) 2024-12-18
WO2014160463A1 (en) 2014-10-02
JP7043530B2 (ja) 2022-03-29
US20160046675A1 (en) 2016-02-18
AU2023200712A1 (en) 2023-03-09
JP6703475B2 (ja) 2020-06-03
RU2015142981A (ru) 2017-04-17
CN105473604B (zh) 2021-01-22
EP4421177A2 (en) 2024-08-28
US11981707B2 (en) 2024-05-14
RU2015142981A3 (enExample) 2018-03-14
WO2014160463A8 (en) 2015-10-08
BR112015022375A2 (pt) 2017-10-10
AU2021201468A1 (en) 2021-03-25
HUE067333T2 (hu) 2024-10-28
US20220002351A1 (en) 2022-01-06
EP2970398A1 (en) 2016-01-20
PL2970398T3 (pl) 2024-09-16
KR20220139415A (ko) 2022-10-14
KR20150127102A (ko) 2015-11-16
RS65760B1 (sr) 2024-08-30
US20250368690A1 (en) 2025-12-04
KR20250023601A (ko) 2025-02-18
RU2761631C2 (ru) 2021-12-13
CN112851766A (zh) 2021-05-28
JP7503588B2 (ja) 2024-06-20
AU2023200712B2 (en) 2025-02-20
LT2970398T (lt) 2024-08-12
US20180319846A1 (en) 2018-11-08
US10017543B2 (en) 2018-07-10
BR112015022375A8 (pt) 2018-01-23
AU2018282476A1 (en) 2019-01-24
JP2024107243A (ja) 2024-08-08

Similar Documents

Publication Publication Date Title
IL276106A (en) Garp-binding proteins and their uses
HUE067333T2 (hu) Prefúziós RSV F fehérjék és ezek felhasználása
IL261743B (en) and their uses 33–il antibodies against
IL261547B (en) Antibodies against pesidine and their uses
ZA201601430B (en) Insecticidal proteins and methods for their use
ZA201509369B (en) Insecticidal proteins and methods for their use
IL245040B (en) Antibodies against pdgfr-beta and their uses
IL243974B (en) Antibodies against –prlr and uses
IL240034A0 (en) Chimeric proteins based on l1–pd and –pd–l2 and their uses
SG10201709715RA (en) Anti-b7-h5 antibodies and their uses
IL245991A0 (en) 4 Amino-6-(substituted-alkyl-halo)-picolinates and their use as herbicides
IL240177A0 (en) Converted chromium-6-yloxy-cycloalkanes and their use as drugs
EP3029071A4 (en) Saxatilin-fc fusion protein and use thereof
AU2013901331A0 (en) Fusion Proteins and Use Thereof
GB201320209D0 (en) Improvements in or relating to protein Micro-nets